The Application of Combined Immune Checkpoint Inhibitor Modalities in Previously Treated Non-Small Cell Lung Cancer Patients and the Associations Thereof With the Lung Immune Prognostic Index

BACKGROUND: Immune checkpoint inhibitor (ICI) monotherapy remains the standard of care for patients with previously treated non-small cell lung cancer. However, few reports have compared the clinical benefits of second-line ICIs alone with those of ICIs combined with other therapies, including anti-...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Ting, Yang, Xue, Zhao, Jing, Xia, Lixia, Wang, Qiyuan, Jin, Rui, Zhou, Lingxiao, Zhang, Bin, Zhao, Jun, Li, Huijie, Li, Wen, Xia, Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213016/
https://www.ncbi.nlm.nih.gov/pubmed/34150659
http://dx.doi.org/10.3389/fonc.2021.690093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8213016/
https://www.ncbi.nlm.nih.gov/pubmed/34150659
http://dx.doi.org/10.3389/fonc.2021.690093

Ejemplares similares